Embryonics

Embryonics is a company dedicated to participate in privately owned, early-stage biotechnology companies that invent and develop therapies and (companion-) diagnostics in the areas of oncology, neuro-degenerative diseases and virology.
Big pharmaceutical companies are in high need to fill their pipelines in these areas with true innovative approaches they themselves usually do not develop and hence, have to bring in through licenses or acquisitions. These innovative approaches come from research-based, technology oriented small biotech companies. When investing in such companies the highest financial upside, but also most riskfull, is in early stage companies. Therefore a broad diversification among companies and therapeutic fields is needed to spread the risk. The investments should represent the top tiers of biotech universe: oncology, neurogenerative diseases and viral diseases. Embryonics builds a portfolio of 5 to 7 companies in each of the mentioned areas.
Embryonics only participates in companies with true innovative, patent protected approaches, invented by driven, best in-class researchers.